Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06637423 · ClinicalTrials.gov registry record · Phase 1

A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027)

A Phase 1 study of Non-muscle Invasive Bladder Cancer, sponsored by Merck Sharp & Dohme.

Recruiting
Registry status
Phase 1
Development phase
32
Enrollment target
13
Study locations

NCT06637423: Recruiting Phase 1 study of Non-muscle Invasive Bladder Cancer, sponsored by Merck Sharp & Dohme.

NCT06637423 is a Phase 1 study of Non-muscle Invasive Bladder Cancer that is actively recruiting participants, run by Merck Sharp & Dohme. The registered enrollment target is 32 participants, below the 226-participant average among 30 other Non-muscle Invasive Bladder Cancer trials with a reported enrollment target (86% lower). The trial reports 13 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06637423, a Phase 1 study of Non-muscle Invasive Bladder Cancer, is actively recruiting participants, sponsored by Merck Sharp & Dohme.

RECRUITING
Registry status
Phase 1
Development phase
32 participants
Enrollment target
13
Study locations

Study Summary

The goal of the study is to learn about the safety of Sacituzumab Tirumotecan and if people can tolerate it when given in the bladder and find the highest dose that people can take without having certain problems. Researchers will then choose a dose level of Sacituzumab Tirumotecan to use in future studies to learn how well the drug works.

Primary Outcome

DLT will be defined as any drug-related adverse event (AE) observed during the DLT evaluation period (7 weeks). All toxicities will be graded using National Cancer Institute Common Terminology for Adverse Events (NCI CTCAE) version 5.0.

Conditions Studied

Non-muscle Invasive Bladder Cancer

Interventions

  • DRUG Supportive care measures
  • DRUG Sacituzumab tirumotecan
  • DRUG Rescue medication

Study Locations (13)

Val-de-Marne

  • HENRI MONDOR HOSPITAL ( Site 0011) - Créteil
  • Gustave Roussy ( Site 0013) - Villejuif

California

  • Michael G Oefelein Clinical Trials ( Site 0053) - Bakersfield

Florida

  • Moffitt Cancer Center ( Site 0057) - Tampa

Illinois

  • Northwestern University ( Site 0051) - Chicago

Maryland

  • Johns Hopkins University ( Site 0055) - Baltimore

Ontario

  • Princess Margaret Cancer Centre ( Site 0003) - Toronto

Quebec

  • CIUSSS de l'Estrie-CHUS ( Site 0002) - Sherbrooke

Nord

  • Hôpital Claude Huriez ( Site 0012) - Lille

Trial Details

FieldValue
Enrollment Target 32 participants
Start Date 2024-12-20
Est. Completion 2028-07-31
Phase Phase 1
Merck Sharp & Dohme

558 total trials

What NCT06637423 shows while recruiting

NCT06637423 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 32 participants, a relatively small participant target, below the 226-participant average among 30 other Non-muscle Invasive Bladder Cancer trials with a reported enrollment target (86% lower).

The record links to 1 condition, with Non-muscle Invasive Bladder Cancer appearing as the primary indexed condition, and to 3 interventions - of which Supportive care measures is the first listed.

NCT06637423 lists 13 locations in 12 states (Val-de-Marne, California, Florida).

Frequently Asked Questions

What is clinical trial NCT06637423 about?

NCT06637423 is a clinical study titled "A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027)". The goal of the study is to learn about the safety of Sacituzumab Tirumotecan and if people can tolerate it when given in the bladder and find the highest dose that people can take without having certain problems. Researchers will then choose a dose level of Sacituzumab Tirumotecan to use in future ...

What is the current status of trial NCT06637423?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2024-12-20. Estimated completion is 2028-07-31.

What conditions does trial NCT06637423 study?

This clinical trial studies the following conditions: Non-muscle Invasive Bladder Cancer.

What interventions are being tested in trial NCT06637423?

The interventions under investigation include: Supportive care measures (DRUG), Sacituzumab tirumotecan (DRUG), Rescue medication (DRUG).

Who is sponsoring clinical trial NCT06637423?

This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06637423 being conducted?

This trial has 13 study locations across California, Florida, Illinois, Maryland, Ontario. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Non-muscle Invasive Bladder Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06637423's enrollment target sits among peer trials

32 23rd of 30 higher than 8 of 30 other Non-muscle Invasive Bladder Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Non-muscle Invasive Bladder Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02445781 · 32 participants · Early Phase 1

    Differing Levels of Hypoglycemia

  • NCT02792270 · 32 participants · NA

    Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT

  • NCT03068910 · 32 participants · Early Phase 1

    Hyperandrogenemia and Altered Day-night LH Pulse Patterns

  • NCT03208868 · 32 participants · NA

    Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT06637423

Source: ClinicalTrials.gov NCT06637423, the US trial registry maintained by the National Library of Medicine. NCT06637423 (small enrollment · multi site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.